MedTrace Logo

Auditory MMN EEG in TRD in Response to Ketamine

NCT05464264 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-11-29

No results posted yet for this study

Summary

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

Conditions

  • Treatment-resistant Depression (TRD)

Interventions

DRUG

Ketamine

Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    collaborator OTHER

  • Toronto Metropolitan University

    collaborator OTHER

  • Unity Health Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05464264 on ClinicalTrials.gov